Delineated as a CRISPR/Cas9-edited polyclonal knockout cell population, the MYG1 Knockout MCF-7 Polyclonal Cells target the MYG1 gene in the MCF-7 human breast adenocarcinoma cell line. This product comprises a heterogeneous pool of cells carrying independent gene disruptions, offering a robust loss-of-function model that reduces clonal artifact concerns typical of monoclonal derivatives. It is tailored for functional genomics investigations into mitochondrial RNA biology within a well-defined breast cancer context.
MCF-7 is a widely utilized epithelial cell line derived from the pleural effusion of a 69-year-old Caucasian female with metastatic mammary adenocarcinoma. It is a classic model for estrogen receptor-positive luminal A breast cancer, maintaining hormone responsiveness and key features of mammary epithelium. The cell line is adherent and exhibits typical characteristics of transformed breast cells, making it a standard platform for studies on cancer cell biology, hormone signaling, and metabolism.
MYG1 encodes a mitochondrial 3′-5′ exoribonuclease that processes and degrades mitochondrial RNA, thereby controlling the fidelity and turnover of mitochondrial transcripts. This activity critically regulates mitochondrial gene expression, influencing mitochondrial mRNA levels, translation, and the assembly of oxidative phosphorylation (OXPHOS) complexes. The MYG1 protein is transcriptionally governed by NRF1, TFAM, and PGC-1??, while it physically associates with the mitochondrial ribosome and RNA processing complexes. It operates within a network featuring the related exoribonucleases PNPT1 and SUPV3L1 and the mitochondrial RNA polymerase.
In MCF-7 cells, MYG1 disruption enables exploration of how mitochondrial RNA metabolism impacts breast cancer cell physiology. Estrogen receptor-positive breast tumors often display altered mitochondrial function, and MYG1 knockout may perturb RNA processing, leading to defective OXPHOS and metabolic stress. This model can reveal whether mitochondrial RNA surveillance pathways contribute to tumor cell proliferation, survival, or apoptotic susceptibility, providing insights into mitochondrial dysfunction in breast cancer pathogenesis.
Researchers can employ these polyclonal knockout cells to perform RT-qPCR analysis of mitochondrial RNAs, western blotting for OXPHOS complex subunits, Seahorse respirometry to measure oxygen consumption, and mitochondrial DNA copy number quantification. Additional assays include apoptosis evaluation and RNA-seq to capture transcriptome-wide effects. These applications facilitate dissection of the molecular links between mitochondrial RNA metabolism and breast cancer progression. For further information, please contact Ascent Research.
